Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Is there any hope for AIDS?

Mark A Wainberg1

  • 1McGill University AIDS Centre, Lady Davis Institute, Sir Mortimer B. Davis-Jewish General Hospital, Montréal, Que. mark.wainberg@mcgill.ca

Clinical and Investigative Medicine. Medecine Clinique Et Experimentale
|April 6, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Importance of pharmacogenetics in antiretroviral metabolism and drug-transporters].

Virologie (Montrouge, France)·2022
Same author

[L'usage de papier buvard de type « FTA<sup>TM</sup> Classic » pour la détection et le génotypage du VIH chez des hommes ayant des relations sexuelles avec d'autres hommes à Montréal (Québec, Canada)].

Virologie (Montrouge, France)·2021
Same author

Antiretroviral therapy with integrase inhibitors: more options.

Virologie (Montrouge, France)·2020
Same author

Nonhuman Primates and Humanized Mice for Studies of HIV-1 Integrase Inhibitors: A Review.

Pathogens & immunity·2019
Same author

Dolutegravir Monotherapy of Simian Immunodeficiency Virus-Infected Macaques Selects for Several Patterns of Resistance Mutations with Variable Virological Outcomes.

Journal of virology·2018
Same author

Correction for Anstett et al., "HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity".

Journal of virology·2018

Genetic diversity in Human Immunodeficiency Virus type 1 (HIV-1) clades impacts drug resistance. While initial sensitivity to antiretroviral drugs is similar across clades, some subtypes develop resistance more readily, highlighting the need for accessible treatments.

Area of Science:

  • Virology
  • Immunology
  • Infectious Diseases

Background:

  • Human Immunodeficiency Virus type 1 (HIV-1) exhibits significant genetic diversity with distinct clades (A-K, O) prevalent in different global regions.
  • Understanding clade-specific characteristics is crucial for effective HIV-1 management and treatment strategies.

Purpose of the Study:

  • To explore the implications of HIV-1 genetic diversity on antiretroviral drug sensitivity and resistance.
  • To highlight the varying propensities of different HIV-1 clades to develop drug resistance.

Main Methods:

  • Review of existing evidence on HIV-1 clades and their interaction with antiretroviral therapies.
  • Comparative analysis of drug sensitivity and resistance patterns across different HIV-1 subtypes.

Related Experiment Videos

Main Results:

  • Evidence suggests comparable sensitivity to antiretroviral drugs across most HIV-1 clades.
  • Certain HIV-1 subtypes and geographic variants demonstrate a higher propensity for developing resistance to specific antiretroviral drugs.

Conclusions:

  • HIV-1 genetic diversity influences the development of drug resistance, despite similar initial drug sensitivities.
  • Urgent need exists to ensure equitable access to essential anti-HIV drugs globally, irrespective of financial constraints.